Price to sales forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides a brief snapshot of the "Price to sales forward" for Prothena Corporation plc (NASDAQ: PRTA) as found on TradingView. It indicates that the market was closed at the time the data was accessed, and no trades were recorded for this specific metric. The content primarily points to the financial data offered by TradingView for PRTA.
AL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda
DelveInsight's "AL Amyloidosis Pipeline Insight, 2026" report details over 10 companies developing 10+ therapies for AL Amyloidosis, covering clinical trials, mechanisms of action, and FDA approvals. Key developments include orphan drug designation for Attralus, Inc.'s zamubafusp alfa, and Immix Biopharma's completion of patient enrollment for its Phase II NEXICART-2 trial, with topline data expected in Q3 2026. Prothena Corporation plc discontinued development of birtamimab after its Phase 3 trial failed to meet its primary endpoint, while Immix Biopharma received RMAT designation for NXC-201.
PRTA - Prothena Corp Plc Options
This article provides a detailed financial overview of Prothena Corp Plc (PRTA), including its stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's market capitalization, income, sales, and various valuation ratios, alongside its recent earnings performance and analyst recommendations. The data indicates recent price changes and performance over different periods.
Price to earnings forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides financial data, specifically the price-to-earnings forward ratio, for Prothena Corporation plc (NASDAQ:PRTA). It is a brief data point from TradingView's financial overview for the biotechnology company. The content appears to be a stub or a data lookup result rather than an analytical article.
(PRTA) Volatility Zones as Tactical Triggers
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes an exceptional risk-reward short setup and offers multi-timeframe signal analysis to guide trading decisions.
Price to sales forward of Prothena Corp. Plc – MUN:0PT
This article displays the "Price to sales forward" metric for Prothena Corp. Plc (MUN:0PT). It presents the period, value, change, and change percentage for this financial indicator. The content largely consists of a placeholder table for financial data and navigation elements.
Price to book forward of Prothena Corporation plc – NASDAQ:PRTA
This page from TradingView provides financial information for Prothena Corporation plc (NASDAQ: PRTA). It specifically highlights the company's price to book forward metric, offering a snapshot of its financial valuation. The content focuses on market data and financial tools available on the platform for analyzing companies like Prothena.
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides the enterprise value to revenue forward for Prothena Corporation plc (NASDAQ:PRTA). It lists the stock on the Nasdaq Stock Market and includes general information about its financial metrics. The original content appears to be a stub or a section of a larger financial data page on TradingView.
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBIT forward. It presents this metric in a table format, showing the period, value, change, and percentage change. The content appears to be a financial data snippet from a larger platform like TradingView.
Price to book forward of Prothena Corp. Plc – MUN:0PT
This article provides financial data for Prothena Corp. Plc (MUN:0PT), specifically focusing on its "Price to book forward" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating market status and data source information.
Enterprise value to EBITDA forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides current financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBITDA forward metric. The information is presented through TradingView, a financial platform offering various market tools and data. The page indicates that the market is closed and no trades have occurred for PRTA.
Prothena Corp, Parkinson antibody program draws attention for the stock
Prothena Corp (PRTA) is gaining investor attention due to its Parkinson's disease antibody, prasinezumab, developed in partnership with Roche. The company is focused on neurodegenerative diseases, and analysts are closely watching upcoming clinical milestones and the competitive landscape with peers like Eli Lilly and Biogen. Prasinezumab targets alpha-synuclein aggregation, with potential for significant financial upside for Prothena through milestones and royalties if it reaches the market.
Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA)
This article provides an overview of Prothena Corporation plc (NASDAQ: PRTA) stock, including its current price, market capitalization, and analyst forecasts. It details financial performance metrics like earnings per share and revenue for past quarters, and offers information on upcoming earnings reports. The article also addresses frequently asked questions regarding PRTA's stock movements, volatility, and investment considerations.
Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis
Prothena Corporation PLC (PRTA) has a strong financial score of 9.21, ranking 10th in its industry, indicating robust financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 1706.36% to $51.08 million and a net profit increase of 154.36%. While specific detailed financial data like cash and cash equivalents, total assets, and free cash flow for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed, the overall indicators point to strong performance.
Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Prothena Corporation PLC (PRTA), detailing its support and resistance levels, price momentum score, and various technical indicator and moving average signals. As of June 26, 2026, PRTA has a price momentum score of 6.29, trading between resistance at $10.93 and support at $8.42. The analysis indicates a "Buy" signal based on a majority of its technical indicators and moving averages.
Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit
The article discusses Prothena Corporation Plc (NASDAQ:PRTA) and its anticipated shift from a loss to a profit. It examines the company's historical earnings, future growth prospects, and the factors contributing to its expected profitability. This transition is highlighted as a significant development for investors monitoring PRTA's financial performance.
Prothena Corp plc strategy in focus, shares watched against biotech peers
Prothena Corp plc (PRTA) is a late-stage neuroscience biotech company listed on Nasdaq, specializing in antibody therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, and amyloidosis. The company's strategy involves partnerships with major pharmaceutical firms such as Roche, Novo Nordisk, and Bristol Myers Squibb, which help mitigate development risks and provide potential revenue streams. Investors view Prothena as a way to engage with neuroscience innovation, balancing the potential rewards of successful clinical trials with inherent industry risks.
Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Prothena Corporation PLC (PRTA), detailing its earnings forecast score, average price target, and analyst ratings. It highlights that the company's current earnings forecast score is 6.67, ranking 327 out of 389 in its industry, with analysts setting an average price target of $18.50. The piece also includes expected revenue and EPS for upcoming quarters and a peer comparison of analyst ratings.
Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Prothena Corporation PLC (PRTA). It indicates that relevant business segment and regional revenue data have not yet been disclosed by the company. The page displays basic stock information including market cap and current price.
Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Prothena Corporation PLC's (PRTA) dividend and stock split history, noting that no dividend data is available for the past five years and no stock split data is recorded. It highlights the company's current stock price, market capitalization, and links to its financial overview, discussions, analysis, and shareholders sections on TradingKey.
Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Prothena Corporation PLC (PRTA), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholder types and provides data on institutional shareholding over various reporting periods, along with related ETF information.
Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.18, and states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The stock closed at $8.93 with a 5.18% increase on June 18th.
Prothena Corporation PLC (PRTA) Institutional Confidence
Prothena Corporation PLC (PRTA) has a strong institutional confidence score of 10.00, ranking first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 96.24%, an increase of 19.52% quarter-over-quarter. Fidelity Management & Research Company LLC is a significant institutional shareholder, among others.
(PRTA) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Prothena Corporation Plc (NASDAQ: PRTA) using AI models to determine price dynamics and optimal positioning. It highlights weak near-term sentiment but strong long-term prospects, offering distinct institutional trading strategies for different risk profiles. The analysis includes entry zones, target prices, and stop losses for position trading, momentum breakout, and risk hedging strategies.
PRTA - Prothena Corp Plc Stock Price and Quote
This article provides comprehensive financial data, stock performance metrics, and news updates for Prothena Corp Plc (PRTA). It includes details on market capitalization, income, sales, key ratios, analyst ratings, and insider transactions, offering a detailed overview of the company's financial health and market perception. Recent news highlights include earnings reports, clinical trial updates, and corporate announcements.
Prothena Insider Bought Shares Worth $981,300, According to a Recent SEC Filing
An insider at Prothena Corporation PLC recently purchased shares totaling $981,300, according to a recent SEC filing. This transaction occurred on May 26, 2026. The company is a late-stage clinical biotechnology firm focused on protein dysregulation and neurological diseases.
Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA)
Rubric Capital Management LP and David Rosen have collectively disclosed a 9.29% stake in Prothena Corporation plc (PRTA), holding 5,000,000 Ordinary Shares with shared voting and dispositive power. This information comes from a Schedule 13G/A SEC filing, which also indicates that Rubric Capital Master Fund LP has rights to dividends or sale proceeds for over 5% of these shares. The reported ownership is based on 53,832,982 outstanding Ordinary Shares as of March 2, 2026.
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay
Prothena Corporation plc shareholders re-elected two directors, Shane M. Cooke and Dennis J. Selkoe, to the Board until 2029. They also ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026 and approved the compensation of the company's named executive officers in a non-binding advisory vote. The outcomes maintain the existing board structure, audit relationship, and executive pay framework.
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates
Prothena Corp plc, a clinical-stage biotech firm, continues to attract investor attention with its pipeline targeting neurodegenerative diseases like Alzheimer's and ALS. The company is advancing candidates like prasinezumab and birtamimab, focusing on misfolded proteins, and maintains a strong financial position, reducing immediate dilution risks. Prothena's presence on Nasdaq offers US investors direct access to its innovative therapies, which are strategically positioned in a competitive biotech landscape.
Number of shareholders of Prothena Corp. Plc – DUS:0PT
This article provides information about the number of shareholders of Prothena Corp. Plc (DUS:0PT), a biotechnology company listed on the Dusseldorf Stock Exchange. It focuses on offering financial data and market insights for the company.
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Prothena Corporation plc reported its latest quarterly results, with analysts now forecasting revenues of US$83.3m in 2026, a 44% increase year-over-year. Despite beating forecasts, analysts have become more bearish on revenue and earnings per share estimates, cutting EPS predictions significantly. However, the consensus price target remains unchanged at US$21.40, suggesting analysts don't expect a long-term impact on valuation despite the revised short-term outlook.
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Prothena Corporation plc recently reported its quarterly results, leading analysts to update their forecasts. Despite beating expectations, sentiment has become more bearish, with revenue and EPS estimates being cut. However, the consensus price target remains largely unchanged, suggesting analysts don't foresee a long-term impact on the company's valuation, and Prothena is still expected to experience significant revenue growth.
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives
Prothena (PRTA) reported a significant annual net loss of US$244.1 million on only US$9.7 million in revenue for FY 2025, alongside fluctuating quarterly revenues and EPS losses. Despite analyst expectations for strong revenue and earnings growth, the company's losses have widened, challenging the bullish narrative that relies heavily on its pipeline progress and potential milestone payments. The article highlights the gap between the current financial performance and optimistic projections, emphasizing the dependence on successful trial outcomes for its partnered neurology and cardiology programs.
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
This article announces Prothena's third-quarter 2025 financial results and business highlights. It would typically cover key financial figures, progress on clinical trials, and any significant corporate developments from the quarter.
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena reported a net income of $32.7 million for the first quarter of 2026, a significant improvement from a net loss in the prior year, primarily driven by a $50 million milestone payment from Novo Nordisk for coramitug. The company updated its full-year 2026 net cash guidance, anticipating ending the year with approximately $273 million in cash. Prothena highlighted progress in its partnered clinical programs, including Fast Track designation for coramitug and promising updates on prasinezumab for Parkinson's disease, and announced a share repurchase program worth up to $100 million.
Prothena (PRTA) Price Target Increased by 37.50% to 16.83
The article reports that the price target for Prothena (PRTA) has been increased by 37.50% to 16.83. No further details about the company, the analysis, or the reasons for the target increase are available in the provided text.
Prothena Corporation plc (PRTA) Stock Analysis: Biotechnology Innovator with a 99.62% Potential Upside
Prothena Corporation plc (PRTA) is a biotechnology company focused on developing therapies for diseases caused by protein dysregulation, with a substantial potential upside of 99.62% according to current analyst ratings. Despite its early-stage financial metrics, including a negative P/E ratio and challenging revenue growth, the company is advancing several late-stage clinical trials for Parkinson's and transthyretin amyloidosis, supported by collaborations with pharmaceutical giants. Technical indicators suggest an oversold stock, presenting a potential buying opportunity for risk-tolerant investors looking for long-term growth in the biotech sector.
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook
Prothena reported a Q1 2026 net income of $32.7 million, a significant increase from a net loss in Q1 2025, largely due to a $50 million milestone payment from Novo Nordisk for coramitug's Phase 3 enrollment and Fast Track designation. This payment has led Prothena to update its 2026 financial guidance, projecting a reduced net cash used in operating and investing activities and an increased year-end cash balance. The company also highlighted advancements in its partnered clinical programs for Parkinson's and Alzheimer's diseases and initiated a share repurchase program.
Prothena reports first quarter 2026 financial results and business highlights
Prothena (NASDAQ: PRTA) announced its first quarter 2026 financial results and provided business updates. These announcements typically cover key financial metrics, progress on clinical trials, and important corporate milestones achieved during the period. The report helps investors and stakeholders understand the company's performance and future outlook.
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena reported strong financial results for Q1 2026, driven by a $50 million milestone payment from Novo Nordisk for coramitug's Phase 3 enrollment. The company updated its full-year 2026 cash burn guidance, expecting to end the year with approximately $273 million in cash. Key business highlights included advancements in partnered clinical programs for Parkinson's and ATTR amyloidosis, as well as the completion of a Phase 1 study for PRX019.
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook
Prothena (NASDAQ: PRTA) reported a first-quarter 2026 profit of $32.7 million, reversing a $60.2 million loss from the previous year, driven by a $50 million milestone payment from Novo Nordisk and reduced operating expenses. The company also improved its 2026 cash outlook, projecting lower net cash usage and a higher year-end cash balance of approximately $273 million. Prothena is advancing its clinical pipeline, including partnered programs for Parkinson's and Alzheimer's diseases, and has initiated a $100 million share repurchase program.
Prothena (Nasdaq:PRTA) - Stock Analysis
This article provides a detailed stock analysis of Prothena (Nasdaq: PRTA), a late-stage clinical biotechnology company, highlighting its financial health, growth forecasts, and recent news. Analysts currently view the stock as undervalued, with significant projected earnings growth, despite past revenue misses and share price volatility. Key developments include Fast Track Designation for coramitug, changes in leadership, and ongoing clinical trials for various neurodegenerative diseases.
(PRTA) Movement as an Input in Quant Signal Sets
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, suggesting a near-term neutral sentiment but mid-to-long-term strength. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional short setup targeting 14.0% downside with minimal risk.
Prothena announces Novo Nordisk obtains fast track designation from the US FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy
Prothena announced that Novo Nordisk has received Fast Track designation from the U.S. FDA for coramitug (PRX004). This designation is for the treatment of ATTR amyloidosis with cardiomyopathy, a serious and life-threatening condition. The Fast Track program aims to expedite the development and review of drugs for serious or life-threatening conditions.
Prothena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of U.S. financial markets. The company, a late-stage clinical biotechnology firm focused on neurodegenerative and rare peripheral amyloid diseases, will not host a conference call in conjunction with this financial report.
3 Growth Companies Insiders Are Eager To Hold
The article highlights three growth companies—Prothena (PRTA), Pattern Group (PTRN), and Equity Bancshares (EQBK)—that exhibit high insider ownership, signaling strong confidence from those closest to the business. These companies are poised for significant earnings and revenue growth, driven by strategic initiatives, leadership changes, and share repurchase programs, making them potentially appealing to investors. The U.S. market's overall growth and stability provide a favorable environment for such companies.
3 Growth Companies Insiders Are Eager To Hold
This article highlights three growth companies—Prothena (PRTA), Pattern Group (PTRN), and Equity Bancshares (EQBK)—with high insider ownership, indicating strong confidence in their future prospects. Despite varying market caps and operational focuses, all three show significant forecasted earnings and revenue growth, along with strategic initiatives and share repurchase programs, suggesting they may be undervalued or poised for strong performance.
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena announced that Novo Nordisk has received Fast Track Designation from the U.S. FDA for coramitug (PRX004), an amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy (ATTR-CM). This designation aims to expedite the development and review of coramitug, which is currently in Phase 3 clinical trials and addresses a significant unmet medical need for patients with this life-threatening disease. Coramitug is designed to clear existing amyloid deposits and prevent further organ deposition, potentially offering a new therapeutic approach for ATTR-CM.
Liquidity Mapping Around (PRTA) Price Events
Prothena Corporation Plc (NASDAQ: PRTA) is showing a near-term neutral sentiment amidst mid and long-term strength, with support being tested. An exceptional 56.7:1 risk-reward setup targets a 16.1% gain versus a 0.3% risk. AI models have generated three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy.
PRTA SEC Filings - Prothena 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Prothena Corporation plc (NASDAQ: PRTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It features AI-powered summaries to simplify understanding of these regulatory documents for investors. The article highlights recent 8-K filings detailing financial results, program discontinuations, collaboration developments with partners like Novo Nordisk, and governance updates.
